Naz Rahman
Stock Analyst at Maxim Group
(0.15)
# 4,453
Out of 5,126 analysts
35
Total ratings
13.79%
Success rate
-46.7%
Average return
Main Sectors:
Stocks Rated by Naz Rahman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KZIA Kazia Therapeutics | Maintains: Buy | $15 → $20 | $5.79 | +245.42% | 1 | Oct 2, 2025 | |
| AYTU Aytu BioPharma | Maintains: Buy | $9 → $7 | $2.39 | +192.89% | 2 | Sep 25, 2025 | |
| GLMD Galmed Pharmaceuticals | Downgrades: Hold | n/a | $0.66 | - | 1 | Apr 4, 2025 | |
| NVCT Nuvectis Pharma | Initiates: Buy | $17 | $8.89 | +91.23% | 1 | Apr 2, 2025 | |
| SLXN Silexion Therapeutics | Maintains: Buy | $135 → $75 | $1.61 | +4,558.39% | 2 | Mar 20, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $120 → $70 | $28.44 | +146.13% | 5 | Feb 7, 2025 | |
| NRSN NeuroSense Therapeutics | Downgrades: Hold | n/a | $0.94 | - | 2 | Dec 16, 2024 | |
| CING Cingulate | Upgrades: Buy | n/a | $7.70 | - | 4 | Nov 20, 2024 | |
| PALI Palisade Bio | Maintains: Buy | $23 → $8 | $1.64 | +387.80% | 7 | Nov 13, 2024 | |
| PRFX PRF Technologies | Downgrades: Hold | n/a | $2.96 | - | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $12.74 | +253.22% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $140 | $7.14 | +1,860.78% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $477.92 | - | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.38 | - | 3 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.27 | +372.44% | 1 | Feb 25, 2022 |
Kazia Therapeutics
Oct 2, 2025
Maintains: Buy
Price Target: $15 → $20
Current: $5.79
Upside: +245.42%
Aytu BioPharma
Sep 25, 2025
Maintains: Buy
Price Target: $9 → $7
Current: $2.39
Upside: +192.89%
Galmed Pharmaceuticals
Apr 4, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.66
Upside: -
Nuvectis Pharma
Apr 2, 2025
Initiates: Buy
Price Target: $17
Current: $8.89
Upside: +91.23%
Silexion Therapeutics
Mar 20, 2025
Maintains: Buy
Price Target: $135 → $75
Current: $1.61
Upside: +4,558.39%
Viking Therapeutics
Feb 7, 2025
Maintains: Buy
Price Target: $120 → $70
Current: $28.44
Upside: +146.13%
NeuroSense Therapeutics
Dec 16, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.94
Upside: -
Cingulate
Nov 20, 2024
Upgrades: Buy
Price Target: n/a
Current: $7.70
Upside: -
Palisade Bio
Nov 13, 2024
Maintains: Buy
Price Target: $23 → $8
Current: $1.64
Upside: +387.80%
PRF Technologies
Oct 24, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.96
Upside: -
Jul 26, 2024
Initiates: Buy
Price Target: $45
Current: $12.74
Upside: +253.22%
Mar 15, 2024
Maintains: Buy
Price Target: $525 → $140
Current: $7.14
Upside: +1,860.78%
Jan 31, 2024
Downgrades: Hold
Price Target: n/a
Current: $477.92
Upside: -
Nov 17, 2023
Downgrades: Hold
Price Target: n/a
Current: $2.38
Upside: -
Feb 25, 2022
Initiates: Buy
Price Target: $6
Current: $1.27
Upside: +372.44%